Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials

被引：2
|
作者：
Dzimitrowicz, Hannah E. [1 ]
Armstrong, Andrew J. [1 ]
机构：
[1] Duke Univ, Dept Med, Duke Canc Inst Ctr Prostate & Urol Canc, Durham, NC 27708 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 08期
关键词：
ANDROGEN DEPRIVATION THERAPY; QUALITY-OF-LIFE; ABIRATERONE;
D O I：
10.1200/JCO.21.02504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：807 / +
页数：5
相关论文
共 50 条
  • [21] Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
    Sweeney, Christopher J.
    Chen, Yu-Hui
    Carducci, Michael
    Liu, Glenn
    Jarrard, David F.
    Eisenberger, Mario
    Wong, Yu-Ning
    Hahn, Noah
    Kohli, Manish
    Cooney, Matthew M.
    Dreicer, Robert
    Vogelzang, Nicholas J.
    Picus, Joel
    Shevrin, Daniel
    Hussain, Maha
    Garcia, Jorge A.
    DiPaola, Robert S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 737 - 746
  • [22] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
    Arnold Lee
    Targeted Oncology, 2023, 18 : 793 - 800
  • [23] Optimal treatment for metastatic hormone-sensitive prostate cancer
    Omlin, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 18 - 19
  • [24] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
    Lee, Arnold
    TARGETED ONCOLOGY, 2023, 18 (05) : 793 - 800
  • [25] Advancements in the treatment of metastatic hormone-sensitive prostate cancer
    Li, Hengping
    Zhang, Mao
    Wang, Xiangrong
    Liu, Yang
    Li, Xuanpeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Systemic therapy in metastatic hormone-sensitive prostate cancer
    McDonald, Jodie
    O'Brien, Jonathan
    Kostos, Louise
    Lawrentschuk, Nathan
    Azad, Arun A.
    Murphy, Declan
    Chen, Kenneth
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2022, 16 (04) : 234 - 239
  • [27] Treatment options for metastatic hormone-sensitive prostate cancer
    Kostos, Louise
    Murphy, Declan G.
    LANCET ONCOLOGY, 2022, 23 (10): : 1234 - 1235
  • [28] Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
    Smith, Matthew R.
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alekseev, Boris
    Montesa-Pino, Alvaro
    Ye, Dingwei
    Parnis, Francis
    Cruz, Felipe
    Tammela, Teuvo L. J.
    Suzuki, Hiroyoshi
    Utriainen, Tapio
    Fu, Cheng
    Uemura, Motohide
    Mendez-Vidal, Maria J.
    Maughan, Benjamin L.
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12): : 1132 - 1142
  • [29] Treatment of primary cancer in metastatic hormone-sensitive prostate cancer
    Lim, Kylie Y. -Y.
    Alberto, Matthew
    Ranasinghe, Weranja
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2023, 17 (04) : 315 - 323
  • [30] Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer
    Yamada, Yasutaka
    Sakamoto, Shinichi
    Tsujino, Takuya
    Saito, Sinpei
    Sato, Kodai
    Nishimura, Kazuki
    Fukushima, Tatsuo
    Nakamura, Ko
    Yoshikawa, Yuki
    Matsunaga, Tomohisa
    Maenosono, Ryoichi
    Kanesaka, Manato
    Arai, Takayuki
    Sazuka, Tomokazu
    Imamura, Yusuke
    Komura, Kazumasa
    Mikami, Kazuo
    Nakamura, Kazuyoshi
    Fukasawa, Satoshi
    Chiba, Kazuto
    Naya, Yukio
    Nagata, Maki
    Komaru, Atsushi
    Nakatsu, Hiroomi
    Azuma, Haruhito
    Ichikawa, Tomohiko
    PROSTATE INTERNATIONAL, 2025, 13 (01) : 60 - 66
12345